ReportCANCER IMMUNOTHERAPY

Immunogenicity of somatic mutations in human gastrointestinal cancers

See allHide authors and affiliations

Science  29 Oct 2015:
aad1253
DOI: 10.1126/science.aad1253

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

It is unknown whether the human immune system frequently mounts a T-cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TIL) from 9/10 patients with metastatic gastrointestinal cancers contained CD4+ and/or CD8+ T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor. There were no immunogenic epitopes shared between these patients. However, in one patient we identified a human leukocyte antigen (HLA)-C*08:02-restricted T-cell receptor from CD8+ TIL that targeted the KRASG12D hotspot driver mutation found in many human cancers. Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations which could potentially be exploited for the development of highly personalized immunotherapies.

View Full Text